| Date | Title | Description |
| 11.09.2024 | Liquidia Corporation Announces Raise of $67.5 Million from New Common Stock Financings and $32.5 Million Advance from HealthCare Royalty Under Current Financing Agreement | MORRISVILLE, N.C., Sept. 11, 2024 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA) (the “Company” or “Liquidia”), a biopharmaceutical company developing innovative therapies for patients with rare cardiopulmonary diseases, announced ... |
| 13.03.2024 | Liquidia Corporation Reports Full Year 2023 Financial Results and Provides Corporate Update | - |
| 06.03.2024 | Liquidia Corporation to Report Full Year 2023 Financial Results on Wednesday, March 13, 2024 | - |
| 05.01.2024 | Liquidia secures $100 million in new financing | Morrisville-based Liquidia Corp., which is pursuing final regulatory approval for Yutrepia, its treatment for pulmonary arterial hypertension, has secured two agreements that will give the company an additional $100 million in capital.
Liqu... |
| 04.01.2024 | Liquidia Corporation Announces $100 Million in New Financings | - |
| 02.03.2021 | Liquidia Corporation Secures $20.5 Million Debt Facility with Silicon Valley Bank | RESEARCH TRIANGLE PARK, N.C., March 02, 2021 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA) today announced the closing of a debt facility on February 26, 2021, with Silicon Valley Bank, which provides Liquidia with up to $20.5 mil... |
| 26.07.2018 | Liquidia Technologies Prices its IPO at $11 Per Share, Raises $50 Million | A biotechnology company based in the Research Triangle Park has raised $50 million in an initial public offering.
Morrisville-based Liquidia Technologies Inc. sold 4.5 million shares at a price of $11 per share. When it initially filed for ... |
| 26.07.2018 | Liquidia Technologies Prices its IPO at $11 Per Share, Raises $50 Million | A biotechnology company based in the Research Triangle Park has raised $50 million in an initial public offering.
Morrisville-based Liquidia Technologies Inc. sold 4.5 million shares at a price of $11 per share. When it initially filed for ... |
| 01.07.2018 | Liquidia Technologies Files for $57.5 Million IPO | A biotechnology company based in the Research Triangle Park has filed to raise $57.5 million in an initial public offering, according to a filing Thursday with the Securities and Exchange Commission.
Morrisville-based Liquidia Technologies ... |
| 01.07.2018 | Liquidia Technologies Files for $57.5 Million IPO | A biotechnology company based in the Research Triangle Park has filed to raise $57.5 million in an initial public offering, according to a filing Thursday with the Securities and Exchange Commission.
Morrisville-based Liquidia Technologies ... |
| 29.06.2018 | Term Sheet — Friday, June 29 | FLY
Good morning, Term Sheet readers.
Paid Content How can you protect what you can't see? From ExtraHop
At this point, you’re likely tired of my commentary on this topic, so I spoke with an investor who participated in Bird’s latest round ... |
| 16.10.2014 | Venture firm Canaan Partners raises $675 million more; plans to invest in healthcare, tech startups | The company’s had a dozen exits in the same number of months, many of which high profile – portfolio company Labrys Biologics, for instance, was acquired by Teva Pharmaceutical for up to $825 million and Citivas Therapeutics is pending acqu... |
| 15.09.2014 | Raleigh-Durham Roundup: Liquidia, TrueBridge, Citrix, & More | Share Share on Facebook Share on Twitter LinkedIn Email Reprints
Here are this week’s headlines in North Carolina tech and biotech news.
—Nanotechnology company Liquidia Technologies spun out a second company and at the same time, announced... |
| 12.11.2013 | Liquidia spins out new biotech with $25M A round | Liquidia Technologies has spun out a new biotech company in Research Triangle Park, NC, which boasts an early-stage ophthalmology program and $25 million in venture backing from some high-profile investors. Canaan Partners, New Enterprise A... |
| 15.02.2012 | Pharmas, medical device makers set to pitch at CED Life Science conference | A total of 16 companies are scheduled to make presentations, split evenly between pharmaceuticals and medical devices. Here’s a quick rundown of the presenting companies, all of whom are either based in North Carolina’s Research Triangle or... |
| 13.12.2011 | Nanotechnology firm Liquidia partners with PATH on new pneumonia vaccine | Pneumonia vaccines in the United States have all but eliminated childhood pneumococcal disease. But vaccines are too expensive in the developing world. Even when they are available, they do not cover all variations of the bacterium.
Liquidi... |
| 01.09.2011 | Emerging markets: A new driver for nanobiotechnology innovation | This paper AIDS test didn’t come from big pharma. It was developed at Harvard University and spun out as Diagnostics For All, a nonprofit company aimed at making point-of-care diagnostics accessible in the developing world. Walsh, founder a... |
| 24.08.2011 | Nanotechnology in North Carolina: How N.C. became a nanobiotech hub | Silicon Valley, Boston and Houston are the nation’s top three nanotechnology hubs. Silicon Valley and Boston have nanotech companies in various industries, including medicine. Houston excels in energy applications. Raleigh, North Carolina b... |
| 13.04.2011 | RTP venture capital climate improved in Q1 but biotechs still clamor for cash | Promoted
Clinical Care Capacity Planning
Learn how to manage clinical care capacity more efficiently during uncertain times.
SAP
Promoted
This Patient Experience Checklist Is Your Key To Success in 2021
As healthcare systems strive to recov... |
| 30.03.2011 | North Carolina nanotechnology: the big future of working small | North Carolina’s nanotechnology presence doesn’t immediately come to mind when thinking of the country’s biggest nanotech hubs, a skeptic of the industry recently told me.
In a way, he’s right, at least right now. Nanotechnology has found a... |
| 05.03.2011 | Gates Foundation invests $10 million in vaccine firm Liquidia | Nanotechnology company Liquidia Technologies has received a $10 million equity investment from the Bill & Melinda Gates Foundation to support vaccine development and commercialization.
The financing follows the announcement last month o... |
| 04.03.2011 | Liquidia Technologies Receives $10M Investment from Bill & Melinda Gates Foundation | Liquidia Technologies, a Research Triangle Park, North Carolina-based developer of engineered particles for improved delivery of biologics and small molecules for vaccine and therapeutic applications, received a $10m program-related investm... |
| 04.03.2011 | Gates Foundation pumps $10M into NC nanotech company Liquidia | Promoted
Clinical Care Capacity Planning
Learn how to manage clinical care capacity more efficiently during uncertain times.
SAP
Promoted
Telemedicine’s potential to provide healthcare to the world’s most vulnerable
Teladoc Health Head of R... |
| 09.02.2011 | New malaria vaccines to use Liquidia’s nanotechnology | Promoted
Clinical Care Capacity Planning
Learn how to manage clinical care capacity more efficiently during uncertain times.
SAP
Promoted
This Patient Experience Checklist Is Your Key To Success in 2021
As healthcare systems strive to recov... |
| 14.01.2011 | UNC-Chapel Hill researchers close in on synthetic blood | Synthetic blood is moving closer to becoming reality, thanks to new nanotechnology research from the University of North Carolina at Chapel Hill.
A team of UNC scientists have created tiny particles that have some of the properties of red b... |
| 12.01.2011 | UNC nanotech research paves way for synthetic blood | Promoted
Covid-19’s terrible toll on diabetes patients. What can be done?
The public health crisis has undermined the economy and made people with chronic conditions more vulnerable and stressed. Learn more with a new report from Omada Heal... |
| 27.07.2010 | CED NAMES 25 NORTH CAROLINA COMPANIES TO WATCH | Research Triangle Park, NC - July 27, 2010 |
| 20.04.2010 | Liquidia Technologies Expands Series C Financing to $25M | Liquidia Technologies, a Research Triangle Park, North Carolina-based biopharmaceutical company developing particle-based vaccines and therapeutics, has added an additional investor, PPD, Inc., to its Series C financing.
PPD, a global contr... |
| 19.01.2010 | Liquidia Technologies Raises $20M in Series C Financing | Liquidia Technologies,Inc., a Research Triangle Park, North Carolina-based biopharmaceutical company developing particle-based vaccines and therapeutics, has completed a $20m round of Series C financing.
Canaan Partners led the round, which... |
| 18.12.2009 | USA, Liquidia Technologies Receives $3M Grant from National Institute of Standards and Technology | Liquidia Technologies, Inc., a Research Triangle Park, North Carolina-based nanotechnology company, will receive approximately $3m in funding from the U.S. Commerce Department’s National Institute of Standards and Technology (NIST).
The awa... |
| - | Gates Foundation pumps $10M into NC nanotech company Liquidia | Nanotechnology company Liquidia Technologies has received a $10 million equity investment from the Bill & Melinda Gates Foundation to support vaccine development and commercialization.
The financing follows the announcement last month o... |
| - | North Carolina nanotechnology: the big future of working small | North Carolina’s nanotechnology presence doesn’t immediately come to mind when thinking of the country’s biggest nanotech hubs, a skeptic of the industry recently told me.
In a way, he’s right, at least right now. Nanotechnology has found a... |
| - | Venture firm Canaan Partners raises $675 million more; plans to invest in healthcare, tech startups | Menlo Park venture firm Canaan Partners just raised $675 million for its tenth fund – with plans to invest this Fund X mostly in early stage and seed stage startups in both technology and health care.
The majority of Canaan’s healthcare foc... |
| - | Emerging markets: A new driver for nanobiotechnology innovation | Nanotechnology might not be immediately evident in a small, isolated village in India, but Steve Walsh says such a place offers an important example of what drives nanobiomedical innovation.
Residents there don’t have access to major testin... |
| - | RTP venture capital climate improved in Q1 but biotechs still clamor for cash | Early stage life science companies still developing their technologies can fall into a gap: too expensive to be supported by more grants or angel investments yet not far enough along to secure venture capital interest.
In the worst economy ... |
| - | Pharmas, medical device makers set to pitch at CED Life Science conference | Life science companies and investors, let’s make a deal.
The annual CED Life Science Conference kicks off in Raleigh, North Carolina today where small drug developers hope to make the right connection with a big pharmaceutical company or ve... |
| - | Nanotechnology in North Carolina: How N.C. became a nanobiotech hub | The nanotechnology industry mapped out across the United States is full of bubbles — the good kind.
“Nano-metros” identified and mapped by the Project on Emerging Nanotechnologies, or PEN, depicts the nation’s nanotechnology hubs as bubbles... |
| - | UNC nanotech research paves way for synthetic blood | Synthetic blood is moving closer to becoming reality thanks to new nanotechnology research from the University of North Carolina at Chapel Hill.
A team of UNC scientists have created tiny particles that have some of the properties of red bl... |
| - | New malaria vaccines to use Liquidia’s nanotechnology | The next-generation malaria vaccine could be delivered with nanoparticles made through methods developed by Liquidia Technologies.
The nanotech company, based in North Carolina’s Research Triangle Park, has reached a collaboration agreement... |
| - | Nanotechnology firm Liquidia partners with PATH on new pneumonia vaccine | North Carolina nanotechnology company Liquidia Technologies is partnering with nonprofit organization PATH to develop a new pneumonia vaccine that could be deployed globally.
Research Triangle Park-based Liquidia is working with PATH to con... |
